Targeting a specific protein to improve treatment for chondrosarcoma
Official title: ASPH Targeted Therapy for Chondrosarcoma
Funded at Rhode Island Hospital · NIH-10993100 · Data updated 2026-11-12
This study is looking for better ways to help people with chondrosarcoma, a tough bone cancer, by testing new treatments that target a specific protein linked to tumor growth, and patients may have the chance to participate in these exciting trials.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rhode Island Hospital NIH-funded |
| Lab location | 1 site (Providence, United States) |
| Project start | December 22, 2022 |
| Project end | November 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $656,612 |
| NIH project number | 5R01CA270795-03 |
| Project ID | NIH-10993100 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults diagnosed with chondrosarcoma who have limited treatment options.
✕Less likely to help
Patients with other types of cancer or those who do not have chondrosarcoma may not benefit from this research.
What this research studies
This research aims to enhance the survival and quality of life for patients with chondrosarcoma, a challenging bone cancer with limited treatment options. The approach focuses on targeting aspartate β-hydroxylase (ASPH), a protein that is re-expressed in chondrosarcoma and is linked to tumor growth and metastasis. By investigating new treatment strategies that inhibit ASPH and its associated pathways, the research seeks to develop more effective therapies beyond the current reliance on surgery. Patients may be involved in trials assessing these innovative treatments.
Why it matters
Potential benefit: If successful, this research could lead to more effective therapies for chondrosarcoma, significantly improving patient outcomes.
How similar studies have gone: While targeting ASPH is a novel approach in chondrosarcoma treatment, similar strategies have shown promise in other cancers, indicating potential for success.
Where this research is happening
-
Rhode Island Hospital
Providence, United States Active
Researchers
- Principal investigator: Terek, Richard M — Rhode Island Hospital
- Study coordinator: Terek, Richard M
Related research
Other NIH-funded projects on the same topics.
-
ASPH-targeted treatment for chondrosarcoma
A new treatment that targets the ASPH protein is being developed for adults with chondrosarcoma.
-
Integrative histo-genomic analysis to guide cancer risk and targeted therapies with interpretable AI
Researchers are developing an advanced AI-powered approach to map genetic and cellular patterns across breast and cervical cancers to help tailor treatments.
-
Targeted therapy for AML using DHODH inhibitors to boost differentiation and immune response
Aims to help adults with acute myeloid leukemia by using a special drug approach that makes cancer cells act more like normal blood cells and supports the immune system.
-
Adipome biomarkers in obese TNBC mice for targeted therapy
A study in mice explores how fat-derived particles called adipomes influence an aggressive breast cancer type, with the goal of guiding personalized therapies.
-
Enhancing HER2-targeted therapy for resistant breast cancer
This grant explores new ways to overcome resistance to HER2-targeted therapy in people with HER2-positive breast cancer.
-
Metabolic imaging to guide targeted therapy for liver cancer
A clinician-scientist at UPenn is pursuing training to use metabolic imaging to tailor therapy for hepatocellular carcinoma.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.